{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T02:19:13Z","timestamp":1774059553104,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,11]]},"DOI":"10.7759\/cureus.66647","type":"journal-article","created":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T19:34:26Z","timestamp":1723404866000},"source":"Crossref","is-referenced-by-count":3,"title":["Drug-Induced Alopecia Areata From Upadacitinib"],"prefix":"10.7759","author":[{"given":"Alexander H","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas D","family":"Brownstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt CH","year":"2017","unstructured":"Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017, 3:17011. 10.1038\/nrdp.2017.11","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14668","article-title":"JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects","volume":"20","author":"Klein B","year":"2022","unstructured":"Klein B, Treudler R, Simon JC. JAK-inhibitors in dermatology - small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. J Dtsch Dermatol Ges. 2022, 20:19-24. 10.1111\/ddg.14668","journal-title":"J Dtsch Dermatol Ges"},{"key":"ref3","unstructured":"RINVOQ\u00ae (upadacitinib) | Official Healthcare Professional Site. (2022). Accessed. August 11, 2024: https:\/\/www.rinvoqhcp.com\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.05.022","article-title":"Drug-induced alopecia areata: a systematic review","volume":"90","author":"Ezemma O","year":"2024","unstructured":"Ezemma O, Devjani S, Jothishankar B, Kelley KJ, Senna M. Drug-induced alopecia areata: a systematic review. J Am Acad Dermatol. 2024, 90:133-4. 10.1016\/j.jaad.2023.05.022","journal-title":"J Am Acad Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17014","article-title":"A cross-sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system","volume":"63","author":"Ravipati A","year":"2024","unstructured":"Ravipati A, Pradeep T, Tosti A. A cross-sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system. Int J Dermatol. 2024, 63:497-502. 10.1111\/ijd.17014","journal-title":"Int J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2024.100269","article-title":"Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient","volume":"3","author":"Giavina-Bianchi M","year":"2024","unstructured":"Giavina-Bianchi M, Giavina-Bianchi P. Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient. J Allergy Clin Immunol Glob. 2024, 3:100269. 10.1016\/j.jacig.2024.100269","journal-title":"J Allergy Clin Immunol Glob"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S458592","article-title":"Upadacitinib for alopecia areata in different backgrounds: a case series","volume":"17","author":"He X","year":"2024","unstructured":"He X, Yang D, Lai L, Lang J, Wei K, Xiao M. Upadacitinib for alopecia areata in different backgrounds: a case series. Clin Cosmet Investig Dermatol. 2024, 17:565-71. 10.2147\/CCID.S458592","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2023.07.003","article-title":"Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata","volume":"99","author":"Muzy G","year":"2024","unstructured":"Muzy G. Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata. An Bras Dermatol. 2024, 99:483-4. 10.1016\/j.abd.2023.07.003","journal-title":"An Bras Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2304630","article-title":"Complete response of extensive alopecia areata refractory to baricitinib after five months of treatment with upadacitinib","volume":"35","author":"De la Torre-Gomar FJ","year":"2024","unstructured":"De la Torre-Gomar FJ, Velasco-Amador JP, Prados-Carmona \u00c1, Ruiz-Villaverde R. Complete response of extensive alopecia areata refractory to baricitinib after five months of treatment with upadacitinib. J Dermatolog Treat. 2024, 35:2304630. 10.1080\/09546634.2024.2304630","journal-title":"J Dermatolog Treat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/pde.15504","article-title":"Improvement of severe alopecia areata in an adolescent patient on upadacitinib","volume":"41","author":"Ha GU","year":"2024","unstructured":"Ha GU, Kim JH, Jang YH. Improvement of severe alopecia areata in an adolescent patient on upadacitinib. Pediatr Dermatol. 2024, 41:356-8. 10.1111\/pde.15504","journal-title":"Pediatr Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19377","article-title":"Upadacitinib in concurrent Crohn's disease, atopic dermatitis and alopecia areata: a case report","volume":"38","author":"Novielli D","year":"2024","unstructured":"Novielli D, Foti C, Principi M, et al.. Upadacitinib in concurrent Crohn's disease, atopic dermatitis and alopecia areata: a case report. J Eur Acad Dermatol Venereol. 2024, 38:e8-e10. 10.1111\/jdv.19377","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16893","article-title":"Improvement of severe alopecia areata after 9-month baricitinib treatment followed by subsequent use of upadacitinib in a patient with atopic dermatitis","volume":"50","author":"Uchida H","year":"2023","unstructured":"Uchida H, Kamata M, Watanabe A, et al.. Improvement of severe alopecia areata after 9-month baricitinib treatment followed by subsequent use of upadacitinib in a patient with atopic dermatitis. J Dermatol. 2023, 50:e392-3. 10.1111\/1346-8138.16893","journal-title":"J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2023.03.010","article-title":"Dual efficacy of upadacitinib in a patient with concomitant severe atopic dermatitis and alopecia areata","volume":"150","author":"Walls B","year":"2023","unstructured":"Walls B, Reguiai Z. Dual efficacy of upadacitinib in a patient with concomitant severe atopic dermatitis and alopecia areata. Ann Dermatol Venereol. 2023, 150:281-3. 10.1016\/j.annder.2023.03.010","journal-title":"Ann Dermatol Venereol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.02.019","article-title":"Upadacitinib for management of recalcitrant alopecia areata: a retrospective case series","volume":"35","author":"Johnston LA","year":"2023","unstructured":"Johnston LA, Poelman SM. Upadacitinib for management of recalcitrant alopecia areata: a retrospective case series. JAAD Case Rep. 2023, 35:38-42. 10.1016\/j.jdcr.2023.02.019","journal-title":"JAAD Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X231160914","article-title":"Successful treatment of concomitant alopecia universalis and Crohn's disease with upadacitinib: a case report","volume":"11","author":"Johnston LA","year":"2023","unstructured":"Johnston LA, Lu C, Poelman SM. Successful treatment of concomitant alopecia universalis and Crohn's disease with upadacitinib: a case report. SAGE Open Med Case Rep. 2023, 11:2050313X231160914. 10.1177\/2050313X231160914","journal-title":"SAGE Open Med Case Rep"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00889-0","article-title":"Alopecia universalis in an adolescent successfully treated with upadacitinib-a case report and review of the literature on the use of jak inhibitors in pediatric alopecia areata","volume":"13","author":"Ko\u0142cz K","year":"2023","unstructured":"Ko\u0142cz K, \u017bychowska M, Sawi\u0144ska E, Reich A. Alopecia universalis in an adolescent successfully treated with upadacitinib-a case report and review of the literature on the use of jak inhibitors in pediatric alopecia areata. Dermatol Ther (Heidelb). 2023, 13:843-56. 10.1007\/s13555-023-00889-0","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.08.014","article-title":"Effective treatment of alopecia universalis with oral upadacitinib","volume":"31","author":"Youssef S","year":"2023","unstructured":"Youssef S, Bordone LA. Effective treatment of alopecia universalis with oral upadacitinib. JAAD Case Rep. 2023, 31:80-2. 10.1016\/j.jdcr.2022.08.014","journal-title":"JAAD Case Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X221138452","article-title":"Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: a case report","volume":"10","author":"Bourkas AN","year":"2022","unstructured":"Bourkas AN, Sibbald C. Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: a case report. SAGE Open Med Case Rep. 2022, 10:2050313X221138452. 10.1177\/2050313X221138452","journal-title":"SAGE Open Med Case Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16342","article-title":"Assessment of alopecia areata universalis successfully treated with upadacitinib","volume":"62","author":"Gori N","year":"2023","unstructured":"Gori N, Cappilli S, Di Stefani A, Tassone F, Chiricozzi A, Peris K. Assessment of alopecia areata universalis successfully treated with upadacitinib. Int J Dermatol. 2023, 62:e61-3. 10.1111\/ijd.16342","journal-title":"Int J Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16316","article-title":"Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib","volume":"61","author":"Asfour L","year":"2022","unstructured":"Asfour L, Getsos Colla T, Moussa A, Sinclair RD. Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib. Int J Dermatol. 2022, 61:e416-7. 10.1111\/ijd.16316","journal-title":"Int J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15346","article-title":"Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report","volume":"35","author":"Cantelli M","year":"2022","unstructured":"Cantelli M, Martora F, Patruno C, Nappa P, Fabbrocini G, Napolitano M. Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report. Dermatol Ther. 2022, 35:e15346. 10.1111\/dth.15346","journal-title":"Dermatol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0000000000000780","article-title":"Dual efficacy of upadacitinib in 2 patients with concomitant severe atopic dermatitis and alopecia areata","volume":"32","author":"Gambardella A","year":"2021","unstructured":"Gambardella A, Licata G, Calabrese G, De Rosa A, Alfano R, Argenziano G. Dual efficacy of upadacitinib in 2 patients with concomitant severe atopic dermatitis and alopecia areata. Dermatitis. 2021, 32:e85-6. 10.1097\/DER.0000000000000780","journal-title":"Dermatitis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s13223-021-00597-4","article-title":"Atopic dermatitis and risk of autoimmune diseases: a systematic review and meta-analysis","volume":"17","author":"Lu Z","year":"2021","unstructured":"Lu Z, Zeng N, Cheng Y, et al.. Atopic dermatitis and risk of autoimmune diseases: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021, 17:96. 10.1186\/s13223-021-00597-4","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/278719-drug-induced-alopecia-areata-from-upadacitinib","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T19:34:29Z","timestamp":1723404869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/278719-drug-induced-alopecia-areata-from-upadacitinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,11]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.66647","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,11]]}}}